Page 2 - Boxed Warning News Today

The FDA has granted accelerated approval to Imdelltra (tarlatamab-dlle) for extensive stage small cell lung cancer.

The FDA has approved tarlatamab, a novel bispecific T-cell engager, to treat patients with extensive-cell small cell lung cancer (SCLC).

Breakthrough DLL3-Targeting Therapy Regimen for a Major Solid Tumor

Amgen announced that the U.S. Food and Drug Administration has approved IMDELLTRA? for the treatment of adult patients with extensive-stage small cell lung cancer with disease progression on or...

The FDA has granted accelerated approval to Breyanzi (lisocabtagene maraleucel) for the treatment of relapsed or refractory follicular lymphoma.

The Food and Drug Administration approved Imdelltra (tarlatamab) for the treatment of patients with advanced small cell lung cancer that progressed on or after a platinum-based chemotherapy.

/PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the...

NEW YORK, May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company...

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends...